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Background: Extraskeletal myxoid chondrosarcoma (EMC) is a rare subgroup within soft tissue sarcomas. Its
sensitivity to chemotherapy is reported to be low.
Methods: We retrospectively reviewed a series of 11 EMC patients treated as from 2001 within the Italian Rare
Cancer Network (RCN) with anthracycline-based chemotherapy. Pathologic diagnosis was centrally reviewed in all
cases and confirmed by the presence of the specific chromosomal rearrangements,
involving the NR4A3 gene locus on chromosome 9.
Results: Eleven patients treated with anthracycline-based chemotherapy were included (M/F: 9/2 – mean age:
52 years – site of primary: lower limb/other = 9/2 - metastatic = 11 – front line/ further line = 10/1 – anthracycline as
single agent/ combined with ifosfamide = 1/10). Ten patients are evaluable for response. Overall, best response
according to RECIST was: partial response (PR) = 4 (40 %), stable disease (SD) = 3, progressive disease (PD) = 3 cases.
Median PFS was 8 (range 2–10) months.
Conclusions: By contrast to what reported so far, anthracycline-based chemotherapy is active in a distinct
proportion of EMC patients.
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Extraskeletal myxoid chondrosarcoma (EMC) is a very rare
sarcoma of uncertain differentiation [1] that, despite its
name, does not exhibit any cartilaginous differentiation.
EMC usually originates from the deep soft tissue, the thigh
being the most common site [2]. Demicco and Coll. re-
cently reported on 5 cases of molecularly confirmed EMC
arising primarily in the bone [3]. On this basis, they pro-
posed to relabel this tumor as myxochondroid sarcoma, ei-
ther osseous or extraskeletal.
Microscopically, EMC can be subdivided into a conven-
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article, unless otherwise stated.the latter being marked by the presence of a predominantly
epithelioid morphology, high mitotic rate and necrosis [1].
Cases of dedifferentiated ECM were also described [4].
EMC is marked by a specific chromosomal rearrange-
ments, involving the NR4A3 gene locus on chromosome 9
[1,5]. More often NR4A3 (also called CHN or TEC) is fused
to EWSR on chromosome 22 [6,7], although four chimeric
variants were described to date [4,8,9]. NR4A3 translocation
is relevant in case of differential diagnosis with other
myxoid-mesenchymal neoplasms [10].
The natural history of the EMC is marked by a relatively
indolent behavior with a 10-year survival rate ranging be-
tween 65% and 85%, and 40% risk of metastases at 10 years
[11,12], lung being the most frequent site of secondary
lesions.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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sensitive to cytotoxic chemotherapy [11-15].
We herein report on a retrospective series of 11 patients
with locally advanced/metastatic EMC, molecularly con-
firmed by the presence of NR4A3 rearrangement, treated
with anthracycline-based chemotherapy at our institution
and within the Italian Rare Cancer Network.Methods
Patients selection
We retrospectively identified 11 patients with progressive,
metastatic, molecularly confirmed EMC treated with
anthracycline-based chemotherapy at Fondazione IRCCS
Istituto Nazionale Tumori, Milano and those included in
the data-base of the Italian Rare Cancer Network, regis-
tered by other Italian institutions, from January 2001 to
June 2013. The analysis was approved by the Institutional
Ethics Committee.
Pathological diagnosis was centrally reviewed in all cases
by 2 expert pathologists (SP and APDT) and confirmed by
the evidence of NR4A3 rearrangement. All patients had evi-
dence of Eastern Cooperative Oncology Group perform-
ance status (ECOG PS) ≤3 and an adequate bone marrow
and organ function. All patients provided a written in-
formed consent to data collection within the network and
to the treatment. Data were extracted from individual
patient file and analyzed.Pathology and molecular analysis
The diagnosis was rendered according to the last WHO
classification [1]. Immunoprofile assessment was performed
using the antibodies and conditions detailed in Table 1.
FISH was carried out on FFPE tissue samples with
commercially available EWS break apart probe (VYSIS
LSI-EWSR1 dual color break apart) and with two
NR4A3 specific BAC probes (obtained from C.H.O.R.I.
BAC PAC resources): Spectrum Orange labeled RP11-
30 L7 for the 5′ end and Spectrum Green labeled RP11-
30 N20 for the 3′ end of the gene. Probe labeling and
FISH procedure were carried out as previously described
[16]. Cases with a morphology consistent with EMC but
without the evidence of NR4A2 rearrangement were ex-
cluded from this series.Table 1 Immunohistochemistry conditions
Antibody Clone Company Dilution Antigen
retrieval
S100 Polyclonal Dako 1′:4000 citrate buffer, 15′
Synaptophysin DAK-
SYNAP
Dako 1′:200 EDTA, 30′
EMA E29 Dako 1′:250 EDTA, 30′
PPARγ E-8 Santa Cruz
Biotechnology
1′:20 EDTA, 30′Treatment
Patients were treated with anthracyclines as single-agent
(doxorubicin 60–75 mg/smq, i.v., bolus), or in combination
with ifosfamide (epirubicin 105 mg/smq + ifosfamide 9000
mg/smq, i.v., in 3 days). Mesna was added to ifosfamide.
Chemotherapy was administered every 3 weeks, together
with steroids and antiemetics. Prophylactic granulocyte col-
ony stimulating factors were administered.
Treatment was withheld for haematologic grade ≥3 ad-
verse events (AE) and for non haematologic grade ≥2
AE (as defined by the National Cancer Institute Com-
mon Toxicity Criteria, version 3.0) and restarted after
recovery to grade <2 in case of haematologic or grade
<1 in case of non-haematologic.Clinical assessment
Full blood cell count and biochemistry were assessed at
baseline and before every administration. AE were re-
corded. Disease status was assessed at baseline by a whole
body computed tomography scan (CT), a CT or magnetic
resonance (MRI) of the site(s) of disease, and a whole body
bone scan. CT/MRI were repeated after the first 2 or 3 cy-
cles of treatment then every 2–3 months.
Response to treatment was evaluated by Response
Evaluation Criteria in Solid Tumor (RECIST) [17].Statistical analysis
Progression-free survival (PFS) and overall survival (OS)
were estimated with Kaplan-Meyer method [18]. Failure
for PFS was progressive disease according to RECIST, or
death. OS, failure was death due to any cause. For PFS
and OS, patients who interrupted their treatment with-
out evidence of disease progression and underwent
complete surgery were censored at the time of surgery.
Alive patients were censored at the time of the last
contact.Results
Eleven patients with measurable disease were treated with
an anthracycline-based chemotherapy. Five patients with a
previous diagnosis of EMC were not included in this series
since diagnosis was not confirmed by the presence of
NR4A3 rearrangement. Ten patients were evaluable for re-
sponse (in one case treatment was interrupted early due to
toxicity). Main patient characteristics were: male/female 9/
2, mean age 52 years, primary arising from soft tissue/bone
10/1, locally advanced/metastatic 1/10 (lung metastases in
10 cases), ECOG PS ≤2: 11, anthracycline-based chemo-
therapy as front-line/further line: 10/1. Three patients
underwent macroscopic complete surgery after treatment.
Patient characteristics are detailed in Table 2.
Table 2 Patient clinical characteristics and response evaluation
Patient ID Gender Age at time of
chemotherapy (years)
Diagnosis NR4A3
rearrangement
Site of primary
tumor
Staging at time of
initial diagnosis
Site of relapse at the time of
chemotherapy
RECIST
evaluation
PFS
1 F 48 EMC yes thigh localized disease abdomen, LN PR 7*
2 M 56 EMC yes thigh localized disease lung, LN PD 4
3 M 46 EMC yes thigh local + lung lung, LN PR 8
4 M 38 EMC yes leg localized disease lung, bone, liver, soft tissue NV 2
5 M 55 EMC yes leg localized disease lung, LN, soft tissue PR 8
6 F 64 EMC yes thigh localized disease lung SD 10
7 M 69 EMC yes buttock local + lung buttock, lung PR 5*
8 M 55 EMC yes arm local + lung lung, LN SD 7
9 M 51 EMC yes thigh localized disease lung PD 4
10 M 52 EMC yes leg localized disease lung SD 5*
11 M 48 EMC yes sacrum local + lung lung PD 3
*Patient treated with surgery after chemotherapy, censored at the time of surgical resection; M, male; F, female; EMC, extraskeletal myxoid chondrosarcoma; LN, lymphonode; PR, partial response; SD, stable disease; PD,
progressive disease; NV, not evaluable; PFS, progression free survival.
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The median number of cycles of chemotherapy was 4
(range: 1–8). Patients received anthracycline as single agent
in 1 case, in combination with ifosfamide in 10. One patient
stopped his treatment after the first cycle due to toxicity.
Overall, toxicity was as expected, with ≥G2 neutro-
penia in 60% of patients, and nausea, vomiting, asthenia,
fever and mucositis as the main non-haematologic
toxicities.
Pathology and molecular analysis
Immunophenotypic analysis is detailed in Table 3.
All tumors included in this series were positive for
NR4A3 rearrangement. EWS was rearranged in 9 of 11
cases, as shown in Table 3. Five more patients with a previ-
ous diagnosis of EMC were eventually excluded from this
series since diagnosis was not confirmed by the presence of
NR4A3 rearrangement.
Response
Ten patients were assessable for response, as detailed in
Table 2. The best response according to RECIST was: par-
tial response (PR) in 4/10 cases (40%), stable disease (SD)
in 3/10 (30%), with a minor response in one of them. Pro-
gressive disease (PD) was observed in 3/10 (30%) cases. Dis-
ease control rate was 70%. Responses were confirmed at
3 months. Responses were observed in 4 patients treated
with epirubicin plus ifosfamide and in one patient treated
with doxorubicin as a single agent. Figure 1 shows a re-
sponse to doxorubicin as single agent in a previously pro-
gressive patient.
Median OS was 30 months (range 10 mos-13 years). At a
median follow-up of 30 months, the estimated OS at 10-
year was 50%, with 2 patients dead at the time of the present
analysis and one lost to follow-up. The median PFS for the
entire group was 8 months (range 2–10), with 50% patients
progression-free at 6 months (Figure 2). Three patients (pa-
tient 1/7/10, Table 2) underwent complete surgical resectionTable 3 Immunohistochemistry and FISH results
Pt ID S100 Synaptophysin EMA PPARγ
1 - - + strong, diffuse +
2 - - + plurifocal +
3 - - - + weak
4 - + + +
5 - - - +
6 - - - +
7 + not done + +
8 - - + +
9 + focal - + focal +
10 - - + -
11 + not done - not doneafter chemotherapy, with evidence of a new distant relapse
after 24/12/24 months from surgery, respectively.Discussion
We retrospectively analyzed 11 patients with progressing,
advanced, molecularly confirmed EMC, treated with
anthracycline-based chemotherapy since 2001 within the
Italian Rare Cancer Network. We observed 4 RECIST PR
out of 10 patients evaluable for response, with a median
PFS of 8 months and 50% patients progression-free at
6 months. As EMC is an extremely rare mesenchymal ma-
lignancy, rare cancer networks represent a valuable tool in
order to collect case series, in addition to sharing and de-
veloping clinical expertise.
In fact, EMC represents a small subgroup among sar-
comas and no prospective study focusing on their med-
ical treatment is available as of today. Despite rarity, in
order to collect an homogeneous series, we decided to
include only cases in which diagnosis had been con-
firmed by the presence of NR4A3 rearrangement.
In our series the response rate to anthracycline-based
chemotherapy looks greater than previously reported.
The only responses to chemotherapy were described in
2001 by McGrory in 2 of 6 metastatic EMC patients re-
sponsive to a multi-agent chemotherapy [13], and more
recently by Han who observed a complete remission in
one patient treated with anthracyclines plus ifosfamide
[19]. No objective responses were observed in the two
largest retrospective series published so far, which col-
lected cases selected over a period of 30 years starting
from the 70′s [11,13]. In fact, no patient had a response
amongst 10 treated with doxorubicin and dacarbazine-
based regimens in the MD Anderson’s retrospective study
[13] published in 1995, as well as none of the 21 patients
treated with different regimens, mostly anthracycline-based,
reported by Memorial Sloan Kettering Cancer Center and
Royal Marsden Hospital in 2008 [11]. In the latter analysis,
the best response was represented by stable disease lasting
≥ 6 months in only 25% of cases, with an estimated 40%
median-PFS at 6 months. More recently, Ogura and Coll.
reviewed their institutional series of 22 patients, with no re-
sponse in 4 cases treated with ifosfamide-based chemother-
apy [12]. An explanation for this discrepancy may well be
that diagnostic criteria for EMC have improved in the last
years and possibly older series may have included other
histological types with overlapping morphologies, such as
myoepithelial carcinomas. In particular, the analysis to de-
tect NR3A4 translocation, which is specific of EMC, was
described for the first time in 1985 [5] and was not rou-
tinely used to confirm the diagnosis until recently. It is now
evident that EMC are morphologically and molecularly
distinct from conventional bone chondrosarcoma, whose
lack of sensitivity to chemotherapy is well known [20,21].
baseline + 6 cycles
A1
A2
B1
B2
Figure 1 Response to chemotherapy with epirubicin and ifosfamide. CT scan (arterial phase after contrast medium). Thigh primary
extraskeletal myxoid chondrosarcoma (Panel A1) with concomitant intra-abdominal lymphonodes involvement (Panel A2) at baseline, and after
6 cycles of treatment with epirubicin and ifosfamide (Panel B1 and B2, respectively). The response is marked by a >30% decrease in tumor size
thus classifying for a partial response by RECIST.
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completely unrelated.
As already mentioned, the differential diagnosis is ra-
ther broad and includes malignant myoepithelioma/
myoepithelial carcinoma, whose natural history and che-
mosensitivity is still not well understood [1,22], but also
low grade fibromyxoid sarcoma, myxoid liposarcoma
and synovial sarcoma with myxoid changes [22-24]. Im-
munohistochemical analysis plays an important role:Figure 2 Overall progression free survival (PFS) of patients
treated with anthracycline-based chemotherapy. Median
PFS 8 months.however, there is some degree of overlapping that may
represent an additional challenge [1,24]. Although not
frequently observed, synaptophysin expression [25] has
been recently confirmed by gene expression profiling
analysis [23]. Finally, PPR-gamma, firstly described to be
involved in ECM signaling pathway [23], is also
expressed in many other cancers including myxoid lipo-
sarcomas [26-28], and therefore it can hardly be diag-
nostically helpful. From these findings it appears that
cytogenetic-molecular analysis substantially helps in dis-
tinguishing EMC from other tumor entities. For these
reason, due to the lack of NR4A3 rearrangement, we ex-
cluded 5 of 16 cases initially diagnosed as EMCS accord-
ing to morphology/immunohistochemistry.
EMCS is an indolent disease and in some cases it
is characterized by a slow progression also in the
metastatic phase, affecting about 40% of cases. How-
ever, in case of advanced and progressive disease, a
medical treatment is needed. Our series suggests that
anthracycline-based chemotherapy can have a role in
this setting. Of note, 3 patients of our series were
completely resected after having a response to
chemotherapy. None of them was cured, but they all
recurred after >12 months from surgery, suggesting
that chemotherapy may have played a role.
In case of resistance to conventional cytotoxic
chemotherapy, further medical treatment are needed
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nitinib in two patients carrying a metastatic EMC
pretreated with chemotherapy [29]. These prelimin-
ary results are under confirmation in a larger series,
while a prospective study on pazopanib, another
antiangiogenic agent, is planned.
Conclusions
By contrast to what reported so far, anthracycline-
based chemotherapy is active in a distinct proportion
of EMC patients. Series like ours may serve as exter-
nal controls for future clinical studies on new agents
in such a rare histology.
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